Please use this identifier to cite or link to this item:
|Title:||MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study|
|Author:||Fox, Robert J.|
Cree, Bruce A.C.
Sèze, Jerome De
Montalbán Gairín, Xavier
Martínez Yélamos, Sergio
|Publisher:||Lippincott, Williams & Wilkins. Wolters Kluwer Health|
|Abstract:||Objective: RESTORE was a randomized, partially placebo-controlled exploratory study evaluating multiple sclerosis (MS) disease activity during a 24-week interruption of natalizumab. Methods: eligible patients were relapse-free through the prior year on natalizumab and had no gadolinium-enhancing lesions on screening brain MRI. Patients were randomized 1:1:2 to continue natalizumab, to switch to placebo, or to receive alternative immunomodulatory therapy (other therapies: IM interferon β-1a [IM IFN-β-1a], glatiramer acetate [GA], or methylprednisolone [MP]). During the 24-week randomized treatment period, patients underwent clinical and MRI assessments every 4 weeks. Results: patients (n = 175) were randomized to natalizumab (n = 45), placebo (n = 42), or other therapies (n = 88: IM IFN-β-1a, n = 17; GA, n = 17; MP, n = 54). Of 167 patients evaluable for efficacy, 49 (29%) had MRI disease activity recurrence: 0/45 (0%) natalizumab, 19/41 (46%) placebo, 1/14 (7%) IM IFN-β-1a, 8/15 (53%) GA, and 21/52 (40%) MP. Relapse occurred in 4% of natalizumab patients and in 15%-29% of patients in the other treatment arms. MRI disease activity recurred starting at 12 weeks (n = 3 at week 12) while relapses were reported as early as 4-8 weeks (n = 2 in weeks 4-8) after the last natalizumab dose. Overall, 50/167 patients (30%), all in placebo or other-therapies groups, restarted natalizumab early because of disease activity. Conclusions: MRI and clinical disease activity recurred in some patients during natalizumab interruption, despite use of other therapies. Classification of evidence: this study provides Class II evidence that for patients with MS taking natalizumab who are relapse-free for 1 year, stopping natalizumab increases the risk of MS relapse or MRI disease activity as compared with continuing natalizumab.|
|Note:||Reproducció del document publicat a: https://doi.org/10.1212/WNL.0000000000000355|
|It is part of:||Neurology, 2014, vol. 82, num. 17, p. 1491-1498|
|Appears in Collections:||Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)|
Articles publicats en revistes (Ciències Clíniques)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.